Amylin analogue (investigational)
A long-acting amylin analogue studied for weight management, often alongside semaglutide (as “CagriSema”).
Early trial interest, particularly combined with semaglutide; still investigational.
Outside trials it is unregulated; gastrointestinal effects are reported in studies.
Investigational — not approved or marketed as a medicine in Australia.
No lawful consumer supply. Legitimate access is only through an approved clinical trial.
This entry is general information about Cagrilintide, not a recommendation to use it. We don’t provide dosing, protocols or sourcing. Speak to a registered practitioner.
This is general education, not medical advice. Peptides.au does not sell, supply, recommend or promote any product or clinic. Always speak with a registered Australian health practitioner before making any health decision.